Protein Corona as a Traslational Barrier in Nanocarrier Desing

Paloma Rial Paz – PhD Student, University of Santiago de Compostela-CiMUS; Philipp Lapuhs – PhD Student, University of Santiago de Compostela-CiMUS; Lucía Sanjurjo Bouza – Post-Doc, Health Research Institute of Santiago de Compostela (IDIS); Huanzhen Ni – Senior Advisor at Eli Lilly Company, Lilly Genetic Medicine, Eli Lilly Company, BOSTON MA, USA., Eli Lilly and Company; Abraham H. Abouzeid – Sr. Director - Molecular Characterization at Eli Lilly Company, BioTDR, Eli Lilly and Company, INDIANAPOLIS IN, USA, Eli Lilly and Company; Faiz Ahmad Mohammed – Director at Eli Lilly and Company, BioTDR, Eli Lilly and Company, INDIANAPOLIS IN, USA, Eli Lilly and Company; Young Ho Song(†) – Executive Director - Drug Delivery, DDCS at Eli Lilly and Company, Drug Delivery, Device and Connected Solutions, Eli Lilly Company, BOSTON MA, USA., Eli Lilly and Company; Anand Subramony – Vice President, Drug Delivery, Device, Connected Solutions & Innovation, Vice President Drug Delivery, Device and Connected Solutions, Eli Lilly Company, INDIANAPOLIS IN, USA., Eli Lilly and Company; María José Alonso Fernández – PI, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain., University of Santiago de Compostela-CiMUS

Introduction:

Nanotechnology-based drug delivery systems, such as liposomes, polymeric nanoparticles, and nanocapsules, improve drug solubility, stability, and biodistribution. However, upon administration in biological fluids, proteins and biomolecules adsorb onto their surface, forming a protein corona [1]. This layer critically influences nanocarrier fate, affecting circulation time, toxicity, and targeting efficiency [2]. Despite stealth strategies such as PEGylation, interactions with biofluids remain unavoidable, underscoring the importance of precise protein corona characterization [3,4].